Never too late: reducing late breast cancer relapse risk

References

• Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on relapse and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123:21-7
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood W, Gelber R, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of relapse for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46
   PubMed Web of Science ®Google Scholar
• Kennecke HF, Olivotto IA, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007;18:45-51
   PubMed Web of Science ®Google Scholar
• Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630-37
   PubMed Web of Science ®Google Scholar
• Lamerato L, Havstad S, Gandhi S, et al. Breast cancer relapse and related mortality in US patients with early breast cancer. J Clin Oncol 2005;23(16S):62s [abstract 738]
   Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008;26:1965-71
   PubMed Web of Science ®Google Scholar
• Jakesz R, Greil R, Gnant Gnant, et al; on behalf of the Austrian Breast and Colorectal Cancer Study Group.Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845-53. Erratum in: J Natl Cancer Inst 2008;100:226
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90
   PubMed Web of Science ®Google Scholar
• Delozier T, Spielmann M, Mace-Lesec’h J, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol 2000;18:3507-12
   Google Scholar
• Delozier T, Spielmann M, Janvier Janvier, et al. Optimal duration of adjuvant tamoxifen (TAM) in early breast cancer (EBC): ten year results of a randomized trial (TAM-01) of the FNCLCC Breast Group. Breast Cancer Res Treat 2005;94 (Suppl 1):S10 [abstract 14]
   Web of Science ®Google Scholar
• Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996;88:1828-33
   PubMed Web of Science ®Google Scholar
• Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 2001;30:56-61
   PubMedGoogle Scholar
• ATLAS & aTTom: Recruitment completed – treatment and follow-up continue. Atlas Newsletter 10. Clinical Trials Service Unit, Oxford UK. Available at: http://www.ctsu.ox.ac.uk/projects/atlas/newsletters/jan05.pdf. [Last accessed 27 August 2007]
   Google Scholar
• Peto R, et al. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women – preliminary results. Breast Cancer Res Treat 2007;100 (Suppl 1): Late-breaking abstract 48
   Google Scholar
• McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br Med J 1995;311:977-80
   Google Scholar
• National Cancer Institute. Clinical announcement: adjuvant therapy of breast cancer - tamoxifen update. Bethesda (MD): National Institutes of Health; 1995. Available at: www.nlm.nih.gov/databases/alerts/tamoxifen.html. [Last accessed 27 August 2007]
   Google Scholar
• Lu Q, Yue W, Wang J, et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998;50:63-71
   PubMed Web of Science ®Google Scholar
• Brodie A, Lu Q, Liu Y, et al. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 1999;6:205-10
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-55
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino Martino, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 2004;22(14S) [abstract 847]
   PubMedGoogle Scholar
• Goss PE, Ingle JN, Martino Martino, et al; National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007;25:2006-11
   PubMed Web of Science ®Google Scholar
• Muss HB. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 2006;100 (Suppl 1):S23 [abstract 102]
   PubMed Web of Science ®Google Scholar
• Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-35
   PubMed Web of Science ®Google Scholar
• Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707-15
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-40
   PubMed Web of Science ®Google Scholar
• Barghout V, Abetz L, Thomas Thomas, et al. Impact of letrozole on quality of life in post-menopausal women with early breast cancer: does age matter? Breast Cancer Res Treat 2005;94 (Suppl 1):S97 [abstract 2040]
   Web of Science ®Google Scholar
• Abetz L, Barghout V, Thomas S, et al. Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study. Breast Cancer Res Treat 2005;94(Suppl 1):S100 [abstract 2047]
   Google Scholar
• National Institute for Health and Clinical Excellence. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. Issue date: November 2006. Available at: www.nice.org/uk/TA112. [Last accessed 27 August 2007]
   Google Scholar
• Fleurence R. An introduction to health economics. Pharm J 2003;271:679-81
   Google Scholar
• Karnon J, Delea T, Johnston SR, et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006;24:237-50
   PubMed Web of Science ®Google Scholar
• Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006;12:374-86
   PubMed Web of Science ®Google Scholar
• Karnon J, di Trapani F, Kaura S. Cost-effectiveness of extended adjuvant letrozole after 5 years of tamoxifen increases with treatment duration. Eur J Cancer Suppl 2007;5:204 [abstract 2.067]
   Google Scholar
• Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99:295-300
   PubMed Web of Science ®Google Scholar
• Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29
   PubMed Web of Science ®Google Scholar
• Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) (German Gynaecological Oncology Research Group) 2008. Guidelines Gynäkologische Onkologie Commission Mamma. English version 08.1.0. Adjuvant Endocrine Postmenopausal. Available at: http://www.ago-online.org/index.php?lang=en&site=mamma_guide_08_1_0&topic=mamma_guide. [Last accessed 8 April 2008]
   Google Scholar
• Ingle J, Tu D, Shepherd L, et al. NCIC CTG MA.17. Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. J Clin Oncol 2006;24(18S): 15s [abstract 549]
   Google Scholar
• Goss P. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab 2006;20(Suppl 1):S5-13
   Google Scholar
• Mamounas EP, Lembersky B, Jeong J-H, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2006;7:416-21
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-36
   PubMed Web of Science ®Google Scholar
• Wengstrom Y, Aapro M, Leto di Priolo S, et al. Patients’ knowledge and experience of adjuvant endocrine therapy for early breast cancer: A European study. Breast 2007;16:462-8
   PubMed Web of Science ®Google Scholar
• Femara® Summary of Product Characteristics; Novartis Pharmaceuticals Ltd. Camberley, Surrey, UK. Available at: http://www.emc.medicines.org.uk [last accessed 4 September 2007]
   Google Scholar
• Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer 2005;5(Suppl 2):S41-5
   PubMedGoogle Scholar